Stem cells and development最新文献

{"title":"Genetically Defined Acute Myeloid Leukemia Induced Pluripotent Stem Cell Clones Reveal Selective Impairment of Hematopoietic Development.","authors":"Deanna P Porras, Amy Qiao, Meaghan Doyle, Hailey Kadonoff, Kinga Vojnits, Diana Golubeva, Cameron G Hollands, Allison Boyd, Mickie Bhatia","doi":"10.1177/15473287261495853","DOIUrl":"https://doi.org/10.1177/15473287261495853","url":null,"abstract":"<p><p>Patient-derived induced pluripotent stem cells (iPSCs) provide a renewable model for studying acute myeloid leukemia (AML), but whether AML-iPSCs faithfully preserve the functional heterogeneity of genetically distinct AML clones remains unclear. Here, we functionally characterized a genetically defined AML-iPSC resource comprising 34 AML-iPSC lines from 11 AML patients, with complementary assays performed across partially overlapping subsets of lines. AML-iPSC lines were classified as aberration-positive (Ab⁺) or aberration-negative (Ab^-) based on retention of the clinically defining patient-specific leukemia-associated genetic abnormalities. Representative Ab⁺ and Ab^- AML-iPSC lines derived from donor hematopoietic cells exhibited comparable differentiation capacity across nonhematopoietic lineages, whereas Ab⁺ AML-iPSC lines demonstrated reduced hematopoietic differentiation, as determined by phenotypic analysis and functional colony-forming assays. Across overlapping subsets of AML-iPSC lines, these clone-specific hematopoietic phenotypes were conserved across four independent differentiation platforms, supporting that they reflect stable clone-specific properties rather than methodological artifacts. Residual hematopoietic progenitors derived from Ab⁺ AML-iPSC lines retained leukemic features, including persistence of leukemia-associated genetic abnormalities, immature blast-like morphology, and enhanced serial replating capacity indicative of self-renewal-associated properties. In a representative paired patient model, these progenitors also demonstrated persistent myeloid-skewed hematopoietic output following xenotransplantation. Together, these findings establish a renewable platform for mechanistic studies investigating how clonal heterogeneity contributes to disease evolution and therapeutic resistance in AML following pluripotent reprogramming.</p>","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"15473287261495853"},"PeriodicalIF":2.0,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Corrigendum to:</i> \"Simplified Derivation of Stable Early Passage Murine Embryonic and Parthenogenetic Stem Cells\".","authors":"","doi":"10.1177/15473287261499779","DOIUrl":"https://doi.org/10.1177/15473287261499779","url":null,"abstract":"","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"15473287261499779"},"PeriodicalIF":2.0,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXM102 Regulates the Multiple Differentiation and Anti-Inflammation of Human Bone Marrow-Derived Leptin Receptor-Positive Stromal Cells <i>In Vitro</i>.","authors":"Dawei Qiu, Junmo Chen, Xiaoyan Liu, Yiran Dai, Yongliang Huang, Tanghua Wang, Ying Zhang, Ziwei Luo","doi":"10.1177/15473287261497533","DOIUrl":"https://doi.org/10.1177/15473287261497533","url":null,"abstract":"<p><p>Bone marrow-derived leptin receptor-expressing (LepR⁺) stromal cells (LepR⁺ BMSCs) have been identified as the primary source of osteoblasts, adipocytes, and fibroblasts in the bone marrow, and they play key roles in the maintenance of the bone marrow microenvironment; however, research on the fate and immunomodulatory changes of human LepR⁺ BMSCs is limited. Here, we isolated LepR⁺ BMSCs from a young donor and studied their fate changes of osteogenic, adipogenic, myogenic differentiation, and immunomodulation with or without CXM102, a novel compound that we have previously demonstrated its anti-osteoporotic effects in mice. Our results showed that CXM102 facilitated a preferential lineage shift toward osteogenesis from adipogenesis of LepR⁺ BMSCs <i>in vitro</i>, as evidenced by increased <i>RUNX 2</i> expression and decreased <i>PPARγ</i> in a bivalent differentiation system. Moreover, interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) were markedly downregulated in HS-5 stromal cells cocultured with conditioned medium from CXM102-treated LepR⁺ BMSCs. Furthermore, CXM102 also inhibited collagen I deposition in LepR⁺ BMSCs when induced into myogenesis. These results demonstrated that CXM102 could promote osteogenesis, but inhibit adipogenesis and myogenesis of LepR⁺ BMSCs, while also showing benign immunomodulation <i>in vitro</i>.</p>","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"15473287261497533"},"PeriodicalIF":2.0,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Diagnostics in Bone Disease: The Potential of Circulating and Stem Cell-Associated miRNAs as Minimally Invasive Biomarkers.","authors":"Seyyed Hossein Khatami, Faezeh Gouhari, Adel Ebrahimpour, Sajad Ehtiati, Ahmad Reza Ahmadi Abdashti, Mohsen Ariannik, Diba Rafienejad, Shahin Talebi, Parasta Heidari, Reza Zandi","doi":"10.1177/15473287261497506","DOIUrl":"https://doi.org/10.1177/15473287261497506","url":null,"abstract":"<p><p>Stem cell-associated microRNAs (miRNAs) have emerged as pivotal regulators of osteogenesis, influencing lineage commitment, differentiation, and skeletal tissue homeostasis. Their dysregulation has been increasingly linked to a spectrum of osteogenic disorders, including osteoporosis, osteoarthritis, and impaired fracture healing. This narrative review synthesizes current evidence on the diagnostic potential of stem cell-associated miRNAs in bone-related pathologies. We highlight their roles in modulating osteoblast and osteoclast activity, maintaining mesenchymal stem cell fate, and orchestrating signaling pathways such as Wnt/β-catenin, bone morphogenetic protein, and Notch. Particular emphasis is placed on circulating miRNAs as minimally invasive biomarkers, offering prospects for early detection, disease stratification, and monitoring therapeutic response. Furthermore, we discuss methodological advances in miRNA profiling, challenges in clinical translation, and the need for standardized validation frameworks. By integrating molecular insights with translational perspectives, this review underscores the promise of stem cell-associated miRNAs as diagnostic tools in osteogenic disorders, while identifying critical gaps that must be addressed to enable their incorporation into precision medicine strategies.</p>","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"15473287261497506"},"PeriodicalIF":2.0,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controller for Maintaining Hematopoietic Stem Cell Stemness: Genetic Information Transmission.","authors":"XinYu Tang, Yan Li, Yan Wang, Ruirong Xu","doi":"10.1177/15473287261490008","DOIUrl":"https://doi.org/10.1177/15473287261490008","url":null,"abstract":"<p><p>Hematopoietic stem cell (HSC) has self-renewal and multilineage differentiation capacities. They sustain lifelong homeostasis and repair of damaged tissues, serving as the core cellular foundation for long-term homeostasis and regenerative repair. Maintaining HSC stemness is essential for normal hematopoiesis; this is not a static property but a dynamically regulated process that directly governs the stable operation of regular hematopoiesis. Recent studies show that HSC quiescence, self-renewal, and lineage differentiation are coordinately controlled by multiple signaling cues. Transcription factor networks, the extracellular matrix, metabolic reprogramming, and epigenetic modifications interact to form a regulatory network that governs stemness maintenance. Under physiological conditions, these factors establish stemness homeostasis; when aberrantly remodeled, they drive diseases such as leukemia and bone marrow failure. This review summarizes the factors that modulate HSC function and stemness during genetic information transmission, and discusses their biological significance. It further elaborates on the regulatory network, compares its distinct patterns in physiological versus pathological states, and explores its translational clinical value. Ultimately, this work aims to provide basic researchers with an integrated conceptual framework and to offer feasible forward-looking strategies for clinical translation.</p>","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"15473287261490008"},"PeriodicalIF":2.0,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational Readiness of Dental Pulp Stem Cell and Extracellular-Vesicle Products: Manufacturing, Delivery, Safety, and Clinical Development.","authors":"Madina A Kurmanalina, Amin Tamadon, Elnara K Ismagulova, Aruzhan M Aitmukhanbetova, Ramazon Safarzoda Sharoffidin","doi":"10.1177/15473287261496095","DOIUrl":"https://doi.org/10.1177/15473287261496095","url":null,"abstract":"<p><p>Dental pulp stem cells (DPSCs), stem cells from human exfoliated deciduous teeth (SHED), and extracellular vesicles (EVs) show regenerative potential, but clinical translation depends on a reproducible product-process-procedure system. This systematic scoping review mapped how DPSC- and EV-containing dental products are defined, manufactured, formulated, dosed, delivered, monitored, and regulated. Following Joanna Briggs Institute guidance (JBI) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR), an umbrella-assisted strategy combined two recent high-coverage reviews with a targeted update through July 15, 2026. Data were charted for source, characterization, carrier, dose, delivery, visualization, safety, outcomes, and manufacturing readiness; a nine-domain review-level framework (Translational Readiness Appraisal for Dental cell and EV products) summarized relative maturity without serving as a validated clinical score. The map comprised 52 unique primary reports and nine methodological or secondary sources. Scaffold-based DPSC/SHED studies generally favored cell-containing constructs, but most were heterogeneous short-term animal experiments. Small human studies of autologous DPSC or SHED products reported encouraging feasibility and few serious safety signals, yet were underpowered for effectiveness or uncommon harms. Dental EV evidence remained predominantly preclinical; isolation, particle-normalized dosing, potency, storage, biodistribution, and batch comparability were frequently incomplete. Magnification was not consistently standardized as a delivery variable. Relative readiness was highest for autologous DPSC pulp products, intermediate for DPSC-scaffold bone or periodontal products, and low for dental EV products. Translation now requires indication-specific potency assays, carrier-product codevelopment, dose-response and biodistribution studies, documented delivery fidelity, standardized outcomes, long-term safety follow-up, and explicit good manufacturing practice (GMP) and regulatory strategies before confirmatory trials.</p>","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"15473287261496095"},"PeriodicalIF":2.0,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumin-Preconditioned Adipose-Derived Stem Cells Improve Cardiac Function in Aged Rats via miR-3575 Modulation.","authors":"Chih-Yang Huang, Wei-Wen Kuo, Tung-Sheng Chen","doi":"10.1177/15473287261474670","DOIUrl":"10.1177/15473287261474670","url":null,"abstract":"<p><p>Aging causes a decrease in cardiac function in living organisms. Although stem cell transplantation shows therapeutic potential for aging hearts, distinct types of evidence have indicated that preconditioning is an effective therapeutic strategy for stem cells to improve tissue regenerative function. This study investigates the therapeutic effect of mesenchymal stem cell preconditioning with curcumin and miR-3575 in the treatment of an aging heart. Cell models have confirmed that preconditioning with curcumin enables stem cells to increase cell viability and CXCR4/p-Akt signal activation. Intervention of miR-3575 mimic significantly enhances viability and CXCR4/p-Akt signal in curcumin preconditioned stem cells. The beneficial effects are suppressed in curcumin preconditioned stem cells receiving miR-3575 inhibitor. The aging animal groups were designed to test the above hypothesis including Aging (rats with 20 months), Aging + ADSC (aging rats receiving adipose-derived stem cells), Aging + Cur-ADSC (aging rats receiving curcumin preconditioned ADSC), Aging + miR mic-ADSC (aging rats receiving miR-3575 mimic preconditioned ADSC), and Aging + miR inh-ADSC (aging rats receiving miR-3575 inhibitor preconditioned ADSC). Compared to Aging, Aging + ADSC slightly improves cardiac function, structure, and pathological protein markers, whereas Aging + Cur-ADSC and Aging + miR mic-ADSC significantly improve the above pathological status. On the other hand, the improvement is suppressed in the ADSC group preconditioned with a miR-3575 inhibitor (Aging + miR inh-ADSC). These findings suggest that ADSC preconditioning with curcumin and miR-3575 shows clinical potential in the treatment of heart failure induced by aging.</p>","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"397-405"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential Role of Mesenchymal Stem Cell Therapy for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Human Clinical Trials.","authors":"Martin Cevallos-Cueva, Laura Ghanem, Taissa Novis, Sakshi Arora, Najwaa Kirmani, Sümeyye Aktaş, Esteban Fernández-Faith","doi":"10.1177/15473287261475857","DOIUrl":"10.1177/15473287261475857","url":null,"abstract":"<p><p>Despite currently available treatment options for moderate-to-severe atopic dermatitis (AD), some patients fail to achieve adequate disease control. Emerging evidence suggests that mesenchymal stem cells (MSCs) may represent a promising therapeutic option. This systematic review and meta-analysis included four randomized controlled trials (RCTs) and one non-randomized clinical trial. Eligible studies evaluated patients with moderate-to-severe AD treated with MSCs derived from human umbilical cord blood, autologous adipose tissue, and allogeneic bone marrow. PubMed, Embase, and Cochrane were searched from inception to December 2025. Primary outcomes included the proportion of patients achieving ≥50% and ≥75% improvement from baseline in the Eczema Area and Severity Index (EASI) and safety outcomes. The meta-analysis included 236 participants. The pooled EASI-50 response rate at week 12 was 46.76% (95% confidence interval [CI]: 32.36% to 61.72%). EASI-75 response rates were 17.41% (95% CI: 5.56% to 43.03%) at week 12 and 23.97% (95% CI: 16.48% to 33.50%) at week 16. The pooled incidence of treatment-emergent adverse events was 26.86% (95% CI: 19.56% to 35.68%), with infections and infestations 7.97% (95% CI: 4.11% to 14.88%) and gastrointestinal disorders 3.52% (95% CI: 1.33% to 9.01%) being the most frequently reported. MSC-based therapy shows early promise as a potential treatment for moderate-to-severe AD, offering a possible alternative to traditional therapies. However, the current evidence is largely based on small clinical trials, underscoring the necessity for large-scale RCTs to establish the efficacy and safety of MSC-based therapy in broader patient populations.</p>","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"377-385"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Umbilical Cord-Derived Cell-Based Interventions for Bronchopulmonary Dysplasia and Related Complications in Preterm Infants: A Bayesian Sparse-Data Meta-Analysis.","authors":"Yonghao Wen, Yunlong Duan, Ru Nie, Siai Chen, Jingxin Yan, Manjun Deng, Haining Fan","doi":"10.1177/15473287261479169","DOIUrl":"10.1177/15473287261479169","url":null,"abstract":"<p><p>Bronchopulmonary dysplasia (BPD) is a major complication of prematurity with limited disease-modifying therapies. We evaluated umbilical cord-derived cell-based interventions for BPD and related complications in preterm infants. This Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020-based systematic review and meta-analysis were registered in PROSPERO. PubMed, Cochrane Library, Web of Science, CNKI, and Wanfang were searched from inception to June 14, 2026. Comparative clinical studies of umbilical cord-derived cell-based interventions in preterm infants at risk of or diagnosed with BPD were included. Outcomes included BPD, BPD severity, death, persistent pulmonary hypertension of the newborn (PPHN), patent ductus arteriosus (PDA), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), late-onset sepsis (LOS), and adverse events (AEs). Bayesian random-effects meta-analysis used a binomial-normal hierarchical model to estimate pooled odds ratios (ORs), 95% credible intervals (CrIs), prediction intervals, and heterogeneity. Twelve studies were included. Umbilical cord-derived cell-based interventions showed a possible protective effect on overall BPD (OR, 0.48; 95% CrI, 0.14-1.20). Stronger associations were observed for severe BPD (OR, 0.17; 95% CrI, 0.01-0.85), moderate or severe BPD (OR, 0.28; 95% CrI, 0.09-0.70), and ROP stage ≥3 (OR, 0.17; 95% CrI, 0.02-0.65). No conclusive benefit or harm was observed for death, PPHN, PDA, IVH, NEC, or LOS. No treatment-related serious AEs were identified. However, prediction intervals were generally wide, and the certainty of evidence was low to very low for most outcomes. Umbilical cord-derived cell-based interventions may reduce the risk of moderate or severe BPD in preterm infants, with an additional potential benefit for ROP stage ≥3. Current evidence remains limited, and larger randomized trials with standardized outcomes and long-term follow-up are needed.</p>","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"386-396"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148803789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing and Dosage of Notch Inhibition and Wnt Activation Enhanced Hair Cell-Like Cell Generation and Stereocilia Elongation in Otic Organoids.","authors":"Hantai Kim, Yeon Ju Kim, Young Sun Kim, Seongjun So, Siung Sung, Sunho Park, Jangho Kim, Kyunghoon Kim, Yun-Hoon Choung, Jungho Ha","doi":"10.1177/15473287261490309","DOIUrl":"https://doi.org/10.1177/15473287261490309","url":null,"abstract":"<p><p>The modulation of Notch and Wnt signaling was evaluated for its ability to promote the differentiation and maturation of hair cell (HC)-like cells in otic organoids derived from mouse embryonic stem cells (mESCs). Using R1/E mESCs, we generated otic organoids and treated them with the Notch pathway inhibitor (γ-secretase inhibitor, DAPT) and the Wnt signaling agonist (CHIR99021) during two-time windows: days (D) D12-D18 (early treatment) or D28-D34 (late treatment). Among the late treatment conditions, lower concentration (5 μM DAPT and 2.5 μM CHIR99021) yielded greater expression of MyoVIIa and Atoh1 compared with higher doses (10 and 5 μM, respectively). Ultrastructural analysis by transmission electron microscopy further demonstrated that late treatment with lower-dose DAPT and CHIR99021 generated HC-like cells harboring longer and more prominent stereocilia-like bundles than those observed in other conditions. In contrast, early treatment produced HCs arranged in a typical otic organoid pattern, resulting in a more morphologically stable but less robustly induced HC-like population. These findings indicate that temporally and dose-controlled modulation of Notch and Wnt signaling efficiently enhances HC-like cell differentiation and stereocilia maturation in mESC-derived otic organoids, providing a useful platform for future studies in inner ear regeneration and cell-based therapies.</p>","PeriodicalId":94214,"journal":{"name":"Stem cells and development","volume":" ","pages":"15473287261490309"},"PeriodicalIF":2.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}